id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1237-0006,FDA,FDA-2016-E-1237,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T05:06:07Z,,0,0,090000648357adda
FDA-2016-E-1237-0005,FDA,FDA-2016-E-1237,"Determination of Regulatory Review Period for Purposes of Patent
Extension; SAVAYSA",Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T15:56:38Z,2017-25703,0,0,0900006482cb67b4
FDA-2016-E-1237-0004,FDA,FDA-2016-E-1237,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-22T04:00:00Z,2017,8,2017-08-22T04:00:00Z,,2017-08-22T11:38:05Z,,0,0,0900006482a92ef5
FDA-2016-E-1237-0003,FDA,FDA-2016-E-1237,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-16T04:00:00Z,2016,8,2016-08-16T04:00:00Z,,2016-08-16T17:14:40Z,,0,0,090000648217a6a2
FDA-2016-E-1237-0001,FDA,FDA-2016-E-1237,"Patent Extension Application from King & Spaulding LLP (on behalf of Daiichi Sankyo Co., Ltd.)",Other,Application,2016-05-09T04:00:00Z,2016,5,2016-05-09T04:00:00Z,,2016-05-09T19:30:50Z,,0,0,0900006481fad5f5
FDA-2016-E-1237-0002,FDA,FDA-2016-E-1237,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-05-09T04:00:00Z,2016,5,2016-05-09T04:00:00Z,,2016-05-09T19:30:55Z,,0,0,0900006481fadb3d